HTG Molecular Diagnostics (HTGMQ) 10-Q 15 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 05, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Trading Symbol	HTGM
Entity Registrant Name	HTG Molecular Diagnostics, Inc
Entity Central Index Key	1,169,987
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		9,525,814

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 2,767,780	$ 7,507,659
Short-term investments available-for-sale, at fair value	2,610,828	4,304,901
Accounts receivable	1,196,129	1,377,441
Inventory, net of allowance of $274,130 at March 31, 2017 and $270,307 at December 31, 2016	1,255,428	1,511,053
Prepaid expenses and other	368,563	433,328
Total current assets	8,198,728	15,134,382
Deferred offering costs	115,062	49,630
Property and equipment, net	3,083,793	3,270,197
Total assets	11,397,583	18,454,209
Current liabilities:
Accounts payable	1,193,217	761,663
Accrued liabilities	1,281,947	1,670,286
Deferred revenue	255,477	335,659
NuvoGen obligation - current	557,634	604,751
Term loan payable - current	6,527,795	6,389,782
Other current liabilities	241,274	258,850
Total current liabilities	10,057,344	10,020,991
Term loan payable - non-current, net of discount and debt issuance costs	3,827,095	5,389,137
NuvoGen obligation - non-current, net of discount	7,914,597	8,017,356
Other non-current liabilities	560,772	619,587
Total liabilities	22,359,808	24,047,071
Commitments and Contingencies
Stockholders’ deficit:
Common stock, $0.001 par value; 200,000,000 shares authorized at March 31, 2017 and December 31, 2016, 8,060,687 shares issued and outstanding, at March 31, 2017, 7,939,967 and 7,938,571 shares issued and outstanding, respectively, at December 31, 2016	8,059	7,938
Additional paid-in-capital	110,452,770	110,081,334
Treasury stock, 0 shares as of March 31, 2017 and 1,396 shares as of December 31, 2016		(75,000)
Accumulated other comprehensive loss	(736)	(1,090)
Accumulated deficit	(121,422,318)	(115,606,044)
Total stockholders’ deficit	(10,962,225)	(5,592,862)
Total liabilities and stockholders' deficit	$ 11,397,583	$ 18,454,209

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Inventory net allowance	$ 274,130	$ 270,307
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	8,060,687	7,939,967
Common stock, shares outstanding	8,060,687	7,938,571
Treasury stock, shares	0	1,396

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue:
Product	$ 541,144	$ 600,190
Service	830,025	265,042
Total revenue	1,371,169	865,232
Cost of revenue	1,295,302	843,470
Gross margin	75,867	21,762
Operating expenses:
Selling, general and administrative	4,238,467	4,693,708
Research and development	1,267,063	1,994,101
Total operating expenses	5,505,530	6,687,809
Operating loss	(5,429,663)	(6,666,047)
Other income (expense):
Interest expense	(398,420)	(392,457)
Interest income	12,089	35,479
Total other income (expense)	(386,331)	(356,978)
Net loss before income taxes	(5,815,994)	(7,023,025)
Provision for income taxes	280	3,399
Net loss	$ (5,816,274)	$ (7,026,424)
Net loss per share, basic and diluted	$ (0.73)	$ (1.02)
Shares used in computing net loss per share, basic and diluted	7,971,097	6,885,522

Condensed Statements of Compreh

Condensed Statements of Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (5,816,274)	$ (7,026,424)
Other comprehensive income, net of tax effect:
Unrealized gain on short and long-term investments	354	39,351
Comprehensive loss	$ (5,815,920)	$ (6,987,073)

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders' Deficit - 3 months ended Mar. 31, 2017 - USD ($)	Total	Common Stock	Additional Paid-In Capital	Treasury Stock	Accumulated Other Comprehensive Loss	Accumulated Deficit
Balance at Dec. 31, 2016	$ (5,592,862)	$ 7,938	$ 110,081,334	$ (75,000)	$ (1,090)	$ (115,606,044)
Balance, shares at Dec. 31, 2016		7,938,571
Exercise of stock options	35,023	$ 13	35,010
Exercise of stock options, shares		13,116
Stock-based compensation expense	396,537		396,537
Vesting of restricted stock units	109	$ 109
Vesting of restricted stock units, shares		109,000
Employee stock purchase plan	14,888		14,888
Retirement of treasury stock		$ (1)	(74,999)	$ 75,000
Net loss	(5,816,274)					(5,816,274)
Unrealized gain on investments	354				354
Balance at Mar. 31, 2017	$ (10,962,225)	$ 8,059	$ 110,452,770		$ (736)	$ (121,422,318)
Balance, shares at Mar. 31, 2017		8,060,687

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating activities
Net loss	$ (5,816,274)	$ (7,026,424)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	296,045	357,023
Accretion of discount on NuvoGen obligation	50,124	52,082
Provision for excess inventory	192,427	30,542
Amortization of Growth Term Loan discount and issuance costs	122,583	102,979
Stock-based compensation expense	396,646	170,048
Employee stock purchase plan expense	14,888
Accretion of incentive from landlord	(35,500)	(23,666)
Accrued interest on available-for-sale securities investments	(5,573)	(7,288)
Changes in operating assets and liabilities:
Accounts receivable	181,312	141,680
Inventory	63,198	(195,203)
Prepaid expenses and other	64,765	119,538
Deferred offering costs	10,830
Accounts payable	311,036	714,361
Accrued liabilities	(388,339)	(537,061)
Deferred revenue	(93,874)	(22,028)
Net cash used in operating activities	(4,635,706)	(6,123,417)
Investing activities
Purchase of property and equipment	(65,385)	(220,570)
Sales, redemptions and maturities of available-for-sale securities	1,700,000	3,000,000
Net cash provided by investing activities	1,634,615	2,779,430
Financing activities
Proceeds from Growth Term Loan		5,000,000
Payments on Growth Term Loan	1,546,612
Payments on capital leases	27,199	27,300
Proceeds from exercise of stock options	35,023
Payments on NuvoGen obligation	200,000
Net cash provided by (used in) financing activities	(1,738,788)	4,972,700
Increase (decrease) in cash and cash equivalents	(4,739,879)	1,628,713
Cash and cash equivalents at beginning of period	7,507,659	3,293,983
Cash and cash equivalents at end of period	2,767,780	4,922,696
Noncash investing and financing activities
Allocation of term loan B warrant discount		122,460
Fixed asset purchases payable and accrued at period end	44,256	1,030,174
Deferred offering costs payable and accrued at period end	76,262
Stock issued for settlement of accrued bonus		(364,910)
Purchase of property and equipment under capital lease		176,360
Incentive from landlord		710,000
Retirement of treasury stock	75,000
Supplemental cash flow information
Cash paid for interest	$ 225,713	$ 237,397

Description of Business

Description of Business	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Description of Business	Note 1. Description of Business HTG Molecular Diagnostics, Inc. (the “Company”) is a commercial stage company that develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The Company derives revenue from services provided by its VERI/O laboratory and sales of the Company’s automation systems and integrated next-generation sequencing-based HTG EdgeSeq assays. The Company operates in one segment and its customers are primarily located in the United States. For the three months ended March 31, 2017 and 2016, approximately 18% and 11%, respectively, of the Company’s revenue was generated from sales to customers located outside of the United States.

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation	Note 2. Basis of Presentation Basis of Presentation The accompanying interim unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect the accounts of the Company as of March 31, 2017 and for the quarters ended March 31, 2017 and 2016. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America (“GAAP”) for complete financial statements. The accompanying interim unaudited, condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows, as of and for the periods presented. The unaudited condensed balance sheet at December 31, 2016 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. These financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the fiscal year ended December 31, 2016, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 23, 2017. Going Concern The Company implemented the criteria of Accounting Standards Update (“ASU”) No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern The Company will need to raise additional capital to fund its operations until its revenue reaches a level sufficient to provide for self-sustaining cash flows. There can be no assurance that additional capital will be available on acceptable terms, or at all, or that the Company’s revenue will reach a level sufficient to provide for self-sustaining cash flows. If sufficient additional capital is not available as and when needed, the Company may have to delay, scale back or discontinue one or more product development programs, curtail its commercialization activities, significantly reduce expenses, sell assets (potentially at a discount to their fair value or carrying value), enter into relationships with third parties to develop or commercialize independently, cease operations altogether, pursue a sale of the Company at a price that may result in up to a total loss on investment for its stockholders, file for bankruptcy or seek other protection from creditors, or liquidate all assets. In addition, if the Company defaults under its term loan agreement, its lenders could foreclose on its assets, including substantially all of its cash and short-term investments which are held in accounts with its lenders. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates include revenue recognition, stock-based compensation expense, the resolution of uncertain tax positions, income tax valuation allowances, recovery of long-lived assets, inventory obsolescence and inventory valuation. Actual results could materially differ from those estimates. Fair Value of Financial Instruments The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which was determined using quoted market prices, broker or dealer quotations or alterative pricing sources with reasonable levels of transparency. The Company’s asset-secured growth capital term loan with Oxford Finance, LLC and Silicon Valley Bank (the “Growth Term Loan”) and its obligation to NuvoGen Research, LLC. (“NuvoGen”) are considered financial instruments. However, the Company is unable to reasonably determine the fair value of these obligations. Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents, available‑for‑sale debt securities and uncollateralized accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and federally secured government money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant. The Company sells its instruments, consumables, sample processing services, custom panel design services and contract research services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The Company had product revenue consisting of revenue from the sale of instruments and consumables for the three months ended March 31, 2017 and 2016, as follows: Three Months Ended March 31, 2017 2016 Instruments $ 22,579 $ 79,181 Consumables 518,565 521,009 Total product revenue $ 541,144 $ 600,190 The Company had service revenue consisting of revenue from custom assay development and sample processing for the three months ended March 31, 2017 and 2016, as follows: Three Months Ended March 31, 2017 2016 Custom assay development $ 81,287 $ — Sample processing 748,738 265,042 Total service revenue $ 830,025 $ 265,042 The Company’s top three customers accounted for 21%, 20% and 17% of the Company’s total revenue for the three months ended March 31, 2017, compared with 32%, 22% and 9% for the three months ended March 31, 2016. The top two customers accounted for approximately 24% and 21% of the Company’s accounts receivable as of March 31, 2017, compared with approximately 28% and 15% as of December 31, 2016. The Company currently relies on a single supplier to supply a subcomponent used in the HTG EdgeSeq processors and a second supplier to provide raw materials used in its HTG EdgeSeq proprietary assays. A loss of either of these suppliers could significantly delay the delivery of products or the completion of services to be performed by our VERI/O laboratory, which in turn would materially affect the Company’s ability to generate revenue. Recently Adopted Accounting Pronouncements In July 2015, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2015-11, Inventory: Simplifying the Measurement of Inventory In April 2016, the FASB issued ASU No. 2016-09, Share-Based Payment: Simplifying the Accounting for Share-Based Payments Recently Issued Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers In March 2016, the FASB issued ASU No. 2016-08, Revenue Recognition: Clarifying the new Revenue Standard’s Principal-Versus-Agent Guidance In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients. The new revenue standard and the standards that amend it will be effective for public entities for fiscal years and interim periods within those fiscal years beginning after December 15, 2017, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is in the initial stages of evaluating the effect of adoption of ASU 2014-09 on its financial statements and continues to evaluate the available transition methods. The Company has begun assessing the standard as it will pertain to its collaborative arrangements with multiple deliverables, which includes performing a detailed review of its existing key contracts and comparing historical accounting policies and practices to the new standard. The Company will continue its evaluation of the standards update through the date of adoption. In February 2016, the FASB issued ASU No. 2016-02, Leases In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments

Inventory

Inventory	3 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Inventory	Note 3. Inventory Inventory, net of allowance, consisted of the following as of the date indicated: March 31, December 31, 2017 2016 Raw materials $ 1,101,821 $ 1,222,437 Work in process 3,761 1,762 Finished goods 423,976 557,161 Total gross inventory 1,529,558 1,781,360 Less inventory allowance (274,130 ) (270,307 ) $ 1,255,428 $ 1,511,053 For the three months ended March 31, 2017 and 2016, the Company recorded net increases in the inventory reserve of $3,823 and $18,237, respectively, to adjust for estimated shrinkage and obsolescence. For the three months ended March 31, 2017 and 2016, increases to the inventory reserve of $192,427 and $30,542 have been included in the cost of revenue, respectively.

Fair Value Instruments

Fair Value Instruments	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Instruments	Note 4. Fair Value Instruments The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which was determined using quoted market prices, broker dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Financial assets and liabilities measured at fair value are classified in their entirety in the fair value hierarchy, based on the lowest level input significant to the fair value measurement. The following table classifies the Company’s financial assets and liabilities measured at fair value on a recurring basis at March 31, 2017 and December 31, 2016, respectively, in the fair value hierarchy: Balance at March 31, 2017 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 2,134,721 $ — $ — $ 2,134,721 Investments available-for-sale at fair value U.S. government obligations $ 1,302,320 $ — $ — $ 1,302,320 Corporate debt securities $ — $ 1,308,508 $ — $ 1,308,508 Total $ 3,437,041 $ 1,308,508 $ — $ 4,745,549 Balance at December 31, 2016 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 6,443,102 $ — $ — $ 6,443,102 Investments available-for-sale at fair value U.S. government obligations $ 1,300,663 $ — $ — $ 1,300,663 Corporate debt securities $ — $ 3,004,238 $ — $ 3,004,238 Total $ 7,743,765 $ 3,004,238 $ — $ 10,748,003 There are no other financial instruments subject to fair value measurement on a recurring basis. Transfers to and from Levels 1, 2 and 3 are recognized at the end of the reporting period. There were no transfers between levels for the three months ended March 31, 2017. Level 1 instruments include investments in federally secured government money market funds and U.S. Treasuries. These instruments are valued using quoted market prices for identical unrestricted instruments in active markets. The Company defines active markets for debt instruments based on both the average daily trading volume and the number of days with trading activity. Level 2 instruments include corporate debt securities. Valuations of Level 2 instruments can be verified to quoted prices, recent trading activity for identical or similar instruments, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. Consideration is given to the nature of the quotations (e.g., indicative or firm) and the relationship of recent market activity to the prices provided from alternative pricing sources. Fair values of these assets are based on prices provided by independent market participants that are based on observable inputs using market-based valuation techniques. These valuation models and analytical tools use market pricing or similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company did not adjust any of the valuations received from these third parties with respect to any of its Level 1 or 2 securities for the periods ended March 31, 2017 or December 31, 2016.

Available for Sale Securities

Available for Sale Securities	3 Months Ended
	Mar. 31, 2017
Investments Debt And Equity Securities [Abstract]
Available for Sale Securities	Note 5. Available for Sale Securities The Company’s portfolio of available-for-sale securities consists of U.S. Treasuries and high credit quality corporate debt securities. The following is a summary of the Company’s available-for-sale securities at March 31, 2017 and December 31, 2016: March 31, 2017 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) U.S. Treasury securities $ 1,302,498 $ - $ (178 ) $ 1,302,320 Corporate debt securities 1,309,066 — (558 ) 1,308,508 Total available-for-sale securities $ 2,611,564 $ - $ (736 ) $ 2,610,828 December 31, 2016 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) U.S. Treasury securities $ 1,300,151 $ 512 $ — $ 1,300,663 Corporate debt securities 3,005,840 — (1,602 ) 3,004,238 Total available-for-sale securities $ 4,305,991 $ 512 $ (1,602 ) $ 4,304,901 The net adjustment to unrealized holding gains on available-for-sale securities, net of tax in other comprehensive income totaled $354 and $39,351 and for the three months ended March 31, 2017 and 2016, respectively. Contractual maturities of debt investment securities at March 31, 2017 are shown below. Expected maturities will differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. Under 1 Year 1 to 2 Years Total U.S. Treasury securities $ 1,302,320 $ — $ 1,302,320 Corporate debt securities 1,308,508 — 1,308,508 Total available-for-sale securities $ 2,610,828 $ — $ 2,610,828 The following table shows the gross unrealized losses and fair values of the Company’s investments that have unrealized losses, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position as of March 31, 2017: Under 1 Year 1 to 2 Years Total Gross Gross Gross Fair Unrealized Fair Unrealized Fair Unrealized Value Losses Value Losses Value Losses U.S. Treasury securities $ 1,302,320 $ (178 ) $ — $ — $ 1,302,320 $ (178 ) Corporate debt securities — — 1,308,508 (558 ) 1,308,508 (558 ) Total available-for-sale securities with unrealized losses $ 1,302,320 $ (178 ) $ 1,308,508 $ (558 ) $ 2,610,828 $ (736 ) For debt securities, the Company determines whether it intends to sell or if it is more likely than not that it will be required to sell impaired securities. This determination considers current and forecasted liquidity requirements, regulatory and capital requirements and securities portfolio management. For all impaired debt securities for which there was no intent or expected requirement to sell, the evaluation considers all available evidence to assess whether it is likely the amortized cost value will be recovered. The Company conducts a regular assessment of its debt securities with unrealized losses to determine whether securities have other-than-temporary impairment considering, among other factors, the nature of the securities, credit rating or financial condition of the issuer, the extent and duration of the unrealized loss, expected cash flows of underlying collateral, market conditions and whether the Company intends to sell or it is more likely than not that the Company will be required to sell the debt securities. The Company did not have any other-than-temporary impairment in its available-for-sale securities at March 31, 2017 or December 31, 2016.

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2017
Property Plant And Equipment [Abstract]
Property and Equipment	Note 6. Property and Equipment Property and equipment, net, consists of the following: March 31, December 31, 2017 2016 Office equipment $ 461,690 $ 447,580 Leasehold improvements 1,847,378 1,847,378 Laboratory and manufacturing equipment 2,732,841 2,659,621 Field equipment 131,096 131,096 Software 150,452 150,451 Construction in progress 199,273 176,963 5,522,730 5,413,089 Less: accumulated depreciation and amortization (2,438,937 ) (2,142,892 ) $ 3,083,793 $ 3,270,197 Depreciation and leasehold improvement amortization expense was $296,045 and $357,023 for the three months ended March 31, 2017 and 2016, respectively.

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2017
Accrued Liabilities Current [Abstract]
Accrued Liabilities	Note 7. Accrued Liabilities Accrued liabilities consist of the following: March 31, December 31, 2017 2016 Employee compensation and benefits $ 750,760 $ 1,088,773 Employee compensation for future absences 201,381 173,533 Interest 71,535 82,591 Professional fees 39,145 79,029 Other 219,126 246,360 $ 1,281,947 $ 1,670,286

Debt Obligations

Debt Obligations	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Debt Obligations	Note 8. Debt Obligations Growth Term Loan There have been no significant modifications to the terms and conditions of the Growth Term Loan since the disclosures made in the Company’s Annual Report on Form-10K, filed with the SEC on March 23, 2017. The remaining principal repayments due under the Growth Term Loan as of March 31, 2017 are as follows for each fiscal year: 2017 $ 4,843,170 2018 5,163,821 Total Growth Term Loan payments 10,006,991 Less discount and deferred financing costs (203,380 ) Plus final fee premium 551,279 Total Growth Term Loan, net $ 10,354,890

Other Agreements

Other Agreements	3 Months Ended
	Mar. 31, 2017
Other Agreements [Abstract]
Other Agreements	Note 9. Other Agreements NuvoGen Obligation There have been no significant modifications to the terms and conditions of the Company’s NuvoGen obligation since the disclosures made in the Company’s Annual Report on Form 10-K, filed with the SEC on March 23, 2017. The minimum remaining payments due to NuvoGen at March 31, 2017 are as follows for each fiscal year, although actual payments could be significantly more than provided in the table in 2018 and beyond, to the extent that 6% of revenue exceeds $400,000: 2017 $ 600,000 2018 400,000 2019 400,000 2020 400,000 2021 400,000 2022 and beyond 6,298,743 Total NuvoGen obligation payments 8,498,743 Less discount (26,512 ) Total NuvoGen obligation, net $ 8,472,231 Development Agreements There have been no significant modifications or financial events relating to the development agreements entered into by the Company in prior periods with Illumina, Inc., Invetech PTY Ltd., and Life Technologies Corporation since the disclosures made by the Company in its Annual Report on Form 10-K, filed with the SEC on March 23, 2017. Collaboration Agreements There have been no significant modifications or financial events relating to the previously disclosed collaboration agreements entered into by the Company with Bristol-Myers Squibb and with Merck KGaA since disclosures made by the Company in its Annual Report on Form 10‑K, filed with the SEC on March 23, 2017. Other Agreements with Related Parties Refer to Note 14 for discussion of agreements with related parties.

Net Loss per Share

Net Loss per Share	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Net Loss per Share	Note 10. Net Loss Per Share Net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock or common stock equivalents outstanding. Accordingly, the numerator and the denominator used in computing both basic and diluted net loss per share for each period are the same. The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss per share for the periods presented: Three Months Ended March 31, 2017 2016 Numerator: Net loss $ (5,816,274 ) $ (7,026,424 ) Denominator: Weighted-average shares outstanding-basic and diluted 7,971,097 6,885,522 Net loss per share, basic and diluted $ (0.73 ) $ (1.02 ) The following outstanding options and warrants were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Three Months Ended March 31, 2017 2016 Options to purchase common stock 1,441,924 1,045,060 Common stock warrant 219,723 219,723 Restricted stock units 256,499 27,500

Stockholders Deficit

Stockholders Deficit	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Stockholders' Deficit	Note 11. Stockholders’ Deficit Treasury Stock In January 2017, the Company’s board of directors approved the retirement of the 1,396 shares of the Company’s common stock previously held in treasury, and returned them to the status of authorized and unissued shares of the Company’s common stock. Stock-based Compensation As of March 31, 2017, there were 110,215 shares available for issuance under the Company’s 2014 Equity Incentive Plan (the “Plan”) and options to purchase 1,441,924 shares of common stock were outstanding, including 674,270 options that were fully vested. As of March 31, 2017, there was total unrecognized compensation expense of $1,181,357 related to unvested stock options, which the Company expects to recognize over a weighted-average period of approximately 1.84 years. A summary of the Plan’s stock option activity is as follows: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at December 31, 2016 1,161,705 $ 3.35 7.7 $ 36,887 Granted 300,500 1.81 Exercised (13,116 ) 2.67 $ 47,025 Forfeited (5,566 ) 3.49 Expired/Cancelled (1,599 ) 6.79 Balance at March 31, 2017 1,441,924 $ 3.03 7.9 $ 5,934,530 Exercisable at March 31, 2017 674,270 $ 3.40 6.5 $ 2,577,267 In January 2017, the Company’s board of directors approved the granting of 211,500 employee incentive stock options. Black-Scholes assumptions used to calculate the fair value of this stock option grant were as follows: Fair value of common stock $ 1.75 Risk-free interest rate 1.92% Expected volatility 61.64% Expected term 5.18 years Expected dividend yield 0% As of March 31, 2017, there were 256,499 restricted stock units (“RSUs”) outstanding, including 55,000 vested and unissued RSUs and 201,499 unvested RSUs. Unrecognized compensation expense related to the remaining unvested RSUs was $384,164 at March 31, 2017, which the Company expects to recognize over a weighted-average remaining service period of 0.6 years. A summary of the Plan’s RSU activity is as follows: Restricted Stock Units (RSU) Weighted- Average Grant Date Fair Value Per Share Balance at December 31, 2016 355,499 $ 2.41 Granted 10,000 1.75 Exercised (109,000 ) 2.44 Balance at March 31, 2017 256,499 $ 2.38 Stock-based compensation expense recorded in the condensed statements of operations for the three months ended March 31, 2017 and 2016 was as follows: Three Months Ended March 31, 2017 2016 Selling, general and administrative $ 279,583 $ 121,550 Research and development 88,361 37,734 Cost of revenue 28,702 10,764 $ 396,646 $ 170,048

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 12. Commitments and Contingencies Legal Matters The Company’s industry is characterized by frequent claims and litigation, including claims regarding intellectual property and product liability. As a result, the Company may be subject to various legal proceedings from time to time. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. Any current litigation is considered immaterial and counter claims have been assessed as remote. Leases The Company leases office and laboratory space in Tucson, Arizona under two non-cancelable operating leases. There have been no changes to the Company’s office and laboratory space leases since the disclosures made by the Company in its Annual Report on Form 10-K, filed with the SEC on March 23, 2017. The Company’s remaining minimum real estate lease payments before common area maintenance charges for each fiscal year as of March 31, 2017 are as follows: 2017 $ 382,544 2018 512,533 2019 514,977 2020 517,457 2021 43,139 $ 1,970,650 As of March 31, 2017, the Company also has capital lease commitments consisting of approximately $104,000 of leases for computer equipment varying in length from 36 to 48 months and an equipment financing arrangement of approximately $21,000 with a vendor that expires in December 2017 that have not been included in the minimum lease payments schedule above. Product Warranty The following is a summary of the Company’s general product warranty liability: Three Months Ended March 31, 2017 2016 Beginning balance $ 50,426 $ 20,213 Cost of warranty claims (173 ) (2,898 ) Warranty accrual (12,561 ) 29,892 Ending balance $ 37,692 $ 47,207 Warranty accrual is included in accrued liabilities in the condensed balance sheets as of March 31, 2017 and December 31, 2016. Expense relating to the recording of this accrual is recorded in cost of revenue within the condensed statements of operations.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Note 13. Income Taxes The Company provides for income taxes based upon management’s estimate of taxable income or loss for each respective period. The Company recognizes an asset or liability for the deferred tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. These temporary differences would result in deductible or taxable amounts in future years, when the reported amounts of the assets are recovered or liabilities are settled, respectively. In each period since inception, the Company has recorded a valuation allowance for the full amount of its net deferred tax assets, as it is not more likely than not that these will be realized. As a result, the Company has not recorded any federal or state income tax benefit in the statements of operations; however, state income tax expense has been recorded for state minimum taxes. The Company periodically reviews its filing positions for all open tax years in all U.S. federal, state and international jurisdictions where the Company is or might be required to file tax returns or other required reports. The Company applies a two-step approach to recognizing and measuring uncertain tax positions. The Company evaluates the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained in a court of last resort. The term “more likely than not” means a likelihood of more than 50 percent. Otherwise, the Company may not recognize any of the potential tax benefit associated with the position. The Company recognizes a benefit for a tax position that meets the more likely than not criterion at the largest amount of tax benefit that is greater than 50 percent likely of being realized upon its effective resolution. Unrecognized tax benefits involve management’s judgment regarding the likelihood of the benefit being sustained. The final resolution of uncertain tax positions could result in adjustments to recorded amounts and may affect the Company’s results of operations, financial position and cash flows. The Company has not identified any uncertain tax positions at March 31, 2017 or December 31, 2016. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties at March 31, 2017 and December 31, 2016, respectively, and has not recognized interest or penalties of significance during the three months ended March 31, 2017 and 2016, respectively, since there are no material unrecognized tax benefits. The Company has not made or had payments due for income taxes for the periods ended March 31, 2017 or December 31, 2016. Management believes no material change to the amount of unrecognized tax benefits will occur within in the next 12 months. The Company has established a valuation allowance against the entire deferred tax asset. A preliminary analysis of past and subsequent equity offerings by the Company, and other transactions that have an impact on the Company’s ownership structure, concluded that the Company may have experienced one or more ownership changes under Sections 382 and 383 of the Internal Revenue Code or IRC. Provisions of the IRC place special limitations on the usage of net operating losses and credits following an ownership change. Such limitations may limit or eliminate the potential future tax benefit to be realized by the Company from its accumulated net operating losses and research and development credits.

Related-Party Transactions

Related-Party Transactions	3 Months Ended
	Mar. 31, 2017
Related Party Transactions [Abstract]
Related-Party Transactions	Note 14. Related-Party Transactions QIAGEN Agreement There have been no significant modifications or financial events relating to the Company’s agreements with QIAGEN Manchester Limited or with QIAGEN North American Holdings, Inc. (“QNAH”) since disclosures made by the Company in its Annual Report on Form 10-K, filed with the SEC on March 23, 2017. As disclosed previously, QNAH agreed to purchase up to an additional $2.0 million of the Company’s common stock (subject to any applicable limitations under the rules of the NASDAQ Stock Market) upon the sale by the Company of at least $12.0 million of common or preferred stock in a financing transaction that occurs prior to May 16, 2017, or such other mutually agreeable date (a “Qualified Financing”). The price per share payable by QNAH in a second tranche closing will be equal to the price per share at which shares are sold in a Qualified Financing.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 15. Subsequent Events Cantor Fitzgerald & Co. Market Offering On April 13, 2017, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor Fitzgerald”), pursuant to which the Company may offer and sell, from time to time, through Cantor Fitzgerald, shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering price of up to $20.0 million (the “ATM Offering”). The shares are being offered and sold pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-216977), which was filed with the SEC in March 2017 and became effective in April 2017. Under the Sales Agreement, Cantor Fitzgerald may sell shares by any method deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended, or any other method permitted by law. As of May 12, 2017, the Company has sold 1,775,367 shares of common stock under the ATM Offering at then-market prices for total gross proceeds of approximately $10.0 million. After sales commissions and other expenses payable by the Company in connection with the ATM Offering, the Company’s aggregate net proceeds through May 12, 2017 were approximately $9.6 million. Legal fees incurred in connection with the S-3 offering of approximately $77,700 have been capitalized as deferred offering costs in the condensed balance sheets as of March 31, 2017. Nasdaq Market Transfer The Company’s common stock is currently listed on The NASDAQ Capital Market under the symbol “HTGM.” Effective April 17, 2017, the listing of the Company’s common stock was transferred to The NASDAQ Capital Market from The NASDAQ Global Market following the Company’s appeal to a NASDAQ Hearings Panel (“Panel”) of the delisting notice received from NASDAQ on February 14, 2017. On April 12, 2017, the Panel found the Company in compliance with the applicable market value of listed securities (MVLS) requirement for listing on The NASDAQ Capital Market. Notwithstanding this result, there can be no assurance that the Company will be able to maintain compliance with the continued listing requirements, including the MVLS requirement, of The NASDAQ Capital Market. Compensatory Arrangements of Certain Officers On April 13, 2017, the Company’s Board of Directors approved a performance-based retention and incentive bonus award (“Bonus Award”) aggregating approximately $302,000 for the Company’s named executive officers. The Bonus Awards are, in part, in consideration of the Company’s performance during 2016, but are expressly conditioned upon the completion by the Company of a financing transaction, or series of related financing transactions, in which the Company raises aggregate gross proceeds in excess of $12.0million and with respect to each named executive officer, his continued employment through the completion of such financing transaction(s) (the “Financing Goal”). No Bonus Awards will be earned or paid if the Financing Goal does not occur. Because payment of the Bonus Awards is expressly conditioned on the Financing Goal, compensation expense related to the Bonus Awards, in excess of the amount accrued as of December 31, 2016 (which accrual was based in part on the determination by the Company’s Board of Directors that the 2016 corporate goals had been achieved at an aggregate level of 47.5%), will be recognized upon consummation of the Financing Goal.

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying interim unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect the accounts of the Company as of March 31, 2017 and for the quarters ended March 31, 2017 and 2016. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America (“GAAP”) for complete financial statements. The accompanying interim unaudited, condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows, as of and for the periods presented. The unaudited condensed balance sheet at December 31, 2016 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. These financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the fiscal year ended December 31, 2016, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 23, 2017.
Going Concern	Going Concern The Company implemented the criteria of Accounting Standards Update (“ASU”) No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern The Company will need to raise additional capital to fund its operations until its revenue reaches a level sufficient to provide for self-sustaining cash flows. There can be no assurance that additional capital will be available on acceptable terms, or at all, or that the Company’s revenue will reach a level sufficient to provide for self-sustaining cash flows. If sufficient additional capital is not available as and when needed, the Company may have to delay, scale back or discontinue one or more product development programs, curtail its commercialization activities, significantly reduce expenses, sell assets (potentially at a discount to their fair value or carrying value), enter into relationships with third parties to develop or commercialize independently, cease operations altogether, pursue a sale of the Company at a price that may result in up to a total loss on investment for its stockholders, file for bankruptcy or seek other protection from creditors, or liquidate all assets. In addition, if the Company defaults under its term loan agreement, its lenders could foreclose on its assets, including substantially all of its cash and short-term investments which are held in accounts with its lenders.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates include revenue recognition, stock-based compensation expense, the resolution of uncertain tax positions, income tax valuation allowances, recovery of long-lived assets, inventory obsolescence and inventory valuation. Actual results could materially differ from those estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which was determined using quoted market prices, broker or dealer quotations or alterative pricing sources with reasonable levels of transparency. The Company’s asset-secured growth capital term loan with Oxford Finance, LLC and Silicon Valley Bank (the “Growth Term Loan”) and its obligation to NuvoGen Research, LLC. (“NuvoGen”) are considered financial instruments. However, the Company is unable to reasonably determine the fair value of these obligations.
Concentration Risks	Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents, available‑for‑sale debt securities and uncollateralized accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and federally secured government money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant. The Company sells its instruments, consumables, sample processing services, custom panel design services and contract research services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The Company had product revenue consisting of revenue from the sale of instruments and consumables for the three months ended March 31, 2017 and 2016, as follows: Three Months Ended March 31, 2017 2016 Instruments $ 22,579 $ 79,181 Consumables 518,565 521,009 Total product revenue $ 541,144 $ 600,190 The Company had service revenue consisting of revenue from custom assay development and sample processing for the three months ended March 31, 2017 and 2016, as follows: Three Months Ended March 31, 2017 2016 Custom assay development $ 81,287 $ — Sample processing 748,738 265,042 Total service revenue $ 830,025 $ 265,042 The Company’s top three customers accounted for 21%, 20% and 17% of the Company’s total revenue for the three months ended March 31, 2017, compared with 32%, 22% and 9% for the three months ended March 31, 2016. The top two customers accounted for approximately 24% and 21% of the Company’s accounts receivable as of March 31, 2017, compared with approximately 28% and 15% as of December 31, 2016. The Company currently relies on a single supplier to supply a subcomponent used in the HTG EdgeSeq processors and a second supplier to provide raw materials used in its HTG EdgeSeq proprietary assays. A loss of either of these suppliers could significantly delay the delivery of products or the completion of services to be performed by our VERI/O laboratory, which in turn would materially affect the Company’s ability to generate revenue.
Recently Adopted and Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements In July 2015, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2015-11, Inventory: Simplifying the Measurement of Inventory In April 2016, the FASB issued ASU No. 2016-09, Share-Based Payment: Simplifying the Accounting for Share-Based Payments Recently Issued Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers In March 2016, the FASB issued ASU No. 2016-08, Revenue Recognition: Clarifying the new Revenue Standard’s Principal-Versus-Agent Guidance In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients. The new revenue standard and the standards that amend it will be effective for public entities for fiscal years and interim periods within those fiscal years beginning after December 15, 2017, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is in the initial stages of evaluating the effect of adoption of ASU 2014-09 on its financial statements and continues to evaluate the available transition methods. The Company has begun assessing the standard as it will pertain to its collaborative arrangements with multiple deliverables, which includes performing a detailed review of its existing key contracts and comparing historical accounting policies and practices to the new standard. The Company will continue its evaluation of the standards update through the date of adoption. In February 2016, the FASB issued ASU No. 2016-02, Leases In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments

Basis of Presentation (Tables)

Basis of Presentation (Tables)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Product Revenue from Sale of Instruments and Consumables and Service Revenue from Custom Assay Development and Sample Processing	The Company had product revenue consisting of revenue from the sale of instruments and consumables for the three months ended March 31, 2017 and 2016, as follows: Three Months Ended March 31, 2017 2016 Instruments $ 22,579 $ 79,181 Consumables 518,565 521,009 Total product revenue $ 541,144 $ 600,190 The Company had service revenue consisting of revenue from custom assay development and sample processing for the three months ended March 31, 2017 and 2016, as follows: Three Months Ended March 31, 2017 2016 Custom assay development $ 81,287 $ — Sample processing 748,738 265,042 Total service revenue $ 830,025 $ 265,042

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory, net of allowance, consisted of the following as of the date indicated: March 31, December 31, 2017 2016 Raw materials $ 1,101,821 $ 1,222,437 Work in process 3,761 1,762 Finished goods 423,976 557,161 Total gross inventory 1,529,558 1,781,360 Less inventory allowance (274,130 ) (270,307 ) $ 1,255,428 $ 1,511,053

Fair Value Instruments (Tables)

Fair Value Instruments (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table classifies the Company’s financial assets and liabilities measured at fair value on a recurring basis at March 31, 2017 and December 31, 2016, respectively, in the fair value hierarchy: Balance at March 31, 2017 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 2,134,721 $ — $ — $ 2,134,721 Investments available-for-sale at fair value U.S. government obligations $ 1,302,320 $ — $ — $ 1,302,320 Corporate debt securities $ — $ 1,308,508 $ — $ 1,308,508 Total $ 3,437,041 $ 1,308,508 $ — $ 4,745,549 Balance at December 31, 2016 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 6,443,102 $ — $ — $ 6,443,102 Investments available-for-sale at fair value U.S. government obligations $ 1,300,663 $ — $ — $ 1,300,663 Corporate debt securities $ — $ 3,004,238 $ — $ 3,004,238 Total $ 7,743,765 $ 3,004,238 $ — $ 10,748,003

Available for Sale Securities (

Available for Sale Securities (Tables)	3 Months Ended
	Mar. 31, 2017
Investments Debt And Equity Securities [Abstract]
Summary of Available-for-sale Securities	The Company’s portfolio of available-for-sale securities consists of U.S. Treasuries and high credit quality corporate debt securities. The following is a summary of the Company’s available-for-sale securities at March 31, 2017 and December 31, 2016: March 31, 2017 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) U.S. Treasury securities $ 1,302,498 $ - $ (178 ) $ 1,302,320 Corporate debt securities 1,309,066 — (558 ) 1,308,508 Total available-for-sale securities $ 2,611,564 $ - $ (736 ) $ 2,610,828 December 31, 2016 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) U.S. Treasury securities $ 1,300,151 $ 512 $ — $ 1,300,663 Corporate debt securities 3,005,840 — (1,602 ) 3,004,238 Total available-for-sale securities $ 4,305,991 $ 512 $ (1,602 ) $ 4,304,901
Summary of Contractual Maturities of Debt Investment Securities	Contractual maturities of debt investment securities at March 31, 2017 are shown below. Under 1 Year 1 to 2 Years Total U.S. Treasury securities $ 1,302,320 $ — $ 1,302,320 Corporate debt securities 1,308,508 — 1,308,508 Total available-for-sale securities $ 2,610,828 $ — $ 2,610,828
Summary of Debt Securities with Unrealized Losses	The following table shows the gross unrealized losses and fair values of the Company’s investments that have unrealized losses, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position as of March 31, 2017: Under 1 Year 1 to 2 Years Total Gross Gross Gross Fair Unrealized Fair Unrealized Fair Unrealized Value Losses Value Losses Value Losses U.S. Treasury securities $ 1,302,320 $ (178 ) $ — $ — $ 1,302,320 $ (178 ) Corporate debt securities — — 1,308,508 (558 ) 1,308,508 (558 ) Total available-for-sale securities with unrealized losses $ 1,302,320 $ (178 ) $ 1,308,508 $ (558 ) $ 2,610,828 $ (736 )

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2017
Property Plant And Equipment [Abstract]
Summary of Property and Equipment	Property and equipment, net, consists of the following: March 31, December 31, 2017 2016 Office equipment $ 461,690 $ 447,580 Leasehold improvements 1,847,378 1,847,378 Laboratory and manufacturing equipment 2,732,841 2,659,621 Field equipment 131,096 131,096 Software 150,452 150,451 Construction in progress 199,273 176,963 5,522,730 5,413,089 Less: accumulated depreciation and amortization (2,438,937 ) (2,142,892 ) $ 3,083,793 $ 3,270,197

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2017
Accrued Liabilities Current [Abstract]
Summary of Accrued Liabilities	Accrued liabilities consist of the following: March 31, December 31, 2017 2016 Employee compensation and benefits $ 750,760 $ 1,088,773 Employee compensation for future absences 201,381 173,533 Interest 71,535 82,591 Professional fees 39,145 79,029 Other 219,126 246,360 $ 1,281,947 $ 1,670,286

Debt Obligations (Tables)

Debt Obligations (Tables)	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Principal Repayments Due Under Term Loan	2017 $ 4,843,170 2018 5,163,821 Total Growth Term Loan payments 10,006,991 Less discount and deferred financing costs (203,380 ) Plus final fee premium 551,279 Total Growth Term Loan, net $ 10,354,890

Other Agreements (Tables)

Other Agreements (Tables)	3 Months Ended
	Mar. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Schedule of Minimum Remaining Payments Due	2017 $ 600,000 2018 400,000 2019 400,000 2020 400,000 2021 400,000 2022 and beyond 6,298,743 Total NuvoGen obligation payments 8,498,743 Less discount (26,512 ) Total NuvoGen obligation, net $ 8,472,231

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Reconciliation of Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Share	The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss per share for the periods presented: Three Months Ended March 31, 2017 2016 Numerator: Net loss $ (5,816,274 ) $ (7,026,424 ) Denominator: Weighted-average shares outstanding-basic and diluted 7,971,097 6,885,522 Net loss per share, basic and diluted $ (0.73 ) $ (1.02 )
Outstanding Options and Warrants Excluded from Computation of Diluted Net Loss per Share	The following outstanding options and warrants were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Three Months Ended March 31, 2017 2016 Options to purchase common stock 1,441,924 1,045,060 Common stock warrant 219,723 219,723 Restricted stock units 256,499 27,500

Stockholders Deficit (Tables)

Stockholders Deficit (Tables)	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Summary of Stock Option Plans Activity	A summary of the Plan’s stock option activity is as follows: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at December 31, 2016 1,161,705 $ 3.35 7.7 $ 36,887 Granted 300,500 1.81 Exercised (13,116 ) 2.67 $ 47,025 Forfeited (5,566 ) 3.49 Expired/Cancelled (1,599 ) 6.79 Balance at March 31, 2017 1,441,924 $ 3.03 7.9 $ 5,934,530 Exercisable at March 31, 2017 674,270 $ 3.40 6.5 $ 2,577,267
Summary of Material Factors Incorporated in Black-Scholes Model In Estimating Fair Value of Options Granted	Black-Scholes assumptions used to calculate the fair value of this stock option grant were as follows: Fair value of common stock $ 1.75 Risk-free interest rate 1.92% Expected volatility 61.64% Expected term 5.18 years Expected dividend yield 0%
Summary of RSU Plans Activity	A summary of the Plan’s RSU activity is as follows: Restricted Stock Units (RSU) Weighted- Average Grant Date Fair Value Per Share Balance at December 31, 2016 355,499 $ 2.41 Granted 10,000 1.75 Exercised (109,000 ) 2.44 Balance at March 31, 2017 256,499 $ 2.38
Summary of Stock-Based Compensation	Stock-based compensation expense recorded in the condensed statements of operations for the three months ended March 31, 2017 and 2016 was as follows: Three Months Ended March 31, 2017 2016 Selling, general and administrative $ 279,583 $ 121,550 Research and development 88,361 37,734 Cost of revenue 28,702 10,764 $ 396,646 $ 170,048

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Minimum Real Estate Lease Payments Before Common Area Maintenance Charges	2017 $ 382,544 2018 512,533 2019 514,977 2020 517,457 2021 43,139 $ 1,970,650
Summary of Product Warranty Liability	The following is a summary of the Company’s general product warranty liability: Three Months Ended March 31, 2017 2016 Beginning balance $ 50,426 $ 20,213 Cost of warranty claims (173 ) (2,898 ) Warranty accrual (12,561 ) 29,892 Ending balance $ 37,692 $ 47,207

Description of Business - Addit

Description of Business - Additional Information (Details) - Segment	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Significant Accounting Policies [Line Items]
Number of operating segments	1
Sales Revenue, Net | Customer Concentration Risk | Customers Located Outside Of United States
Significant Accounting Policies [Line Items]
Sales revenue percentage	18.00%	11.00%

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Details)	May 12, 2017USD ($)	Mar. 31, 2017USD ($)Customer	Mar. 31, 2016Customer	Dec. 31, 2016USD ($)Customer
Significant Accounting Policies [Line Items]
Accumulated deficit		$ 121,422,318		$ 115,606,044
Available cash, cash equivalents and investments in short term available-for-sale securities, amount		5,400,000
Current liabilities		10,057,344		10,020,991
Long-term liabilities		3,827,095		$ 5,389,137
Maximum | Accounting Standards Update 2016-02 | Office and Equipment Leases
Significant Accounting Policies [Line Items]
Gross-up amount of leases effect in balance sheets		$ 3,000,000
Sales Revenue, Net | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer		3	3
Sales Revenue, Net | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage		21.00%	32.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage		20.00%	22.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Three
Significant Accounting Policies [Line Items]
Sales revenue percentage		17.00%	9.00%
Accounts Receivable | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer		2		2
Accounts Receivable | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage		24.00%		28.00%
Accounts Receivable | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage		21.00%		15.00%
Subsequent Event | Sales Agreement
Significant Accounting Policies [Line Items]
Net proceeds from issuance of common stock	$ 9,600,000
Subsequent Event | Sales Agreement | Cantor Fitzgerald & Co
Significant Accounting Policies [Line Items]
Net proceeds from issuance of common stock	$ 9,600,000
NuvoGen | Term Loan Agreement
Significant Accounting Policies [Line Items]
Long-term liabilities		$ 12,300,000

Basis of Presentation - Product

Basis of Presentation - Product Revenue from Sale of Instruments and Consumables (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting Revenue Reconciling Item [Line Items]
Total product revenue	$ 541,144	$ 600,190
Instruments
Segment Reporting Revenue Reconciling Item [Line Items]
Total product revenue	22,579	79,181
Consumables
Segment Reporting Revenue Reconciling Item [Line Items]
Total product revenue	$ 518,565	$ 521,009

Basis of Presentation - Service

Basis of Presentation - Service Revenue from Custom Assay Development and Sample Processing (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting Revenue Reconciling Item [Line Items]
Service	$ 830,025	$ 265,042
Custom assay development
Segment Reporting Revenue Reconciling Item [Line Items]
Service	81,287
Sample processing
Segment Reporting Revenue Reconciling Item [Line Items]
Service	$ 748,738	$ 265,042

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 1,101,821	$ 1,222,437
Work in process	3,761	1,762
Finished goods	423,976	557,161
Total gross inventory	1,529,558	1,781,360
Less inventory allowance	(274,130)	(270,307)
Inventory, net	$ 1,255,428	$ 1,511,053

Inventory - Additional Informat

Inventory - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Inventory Disclosure [Abstract]
Net change in inventory valuation reserves	$ 3,823	$ 18,237
Provision for excess inventory	$ 192,427	$ 30,542

Fair Value Instruments - Financ

Fair Value Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Asset included in:
Financial Assets	$ 4,745,549	$ 10,748,003
Cash and Cash Equivalents | Money Market Securities
Asset included in:
Financial Assets	2,134,721	6,443,102
Investments Available-for-sale at Fair Value | U.S. Government Obligations
Asset included in:
Financial Assets	1,302,320	1,300,663
Investments Available-for-sale at Fair Value | Corporate Debt Securities
Asset included in:
Financial Assets	1,308,508	3,004,238
Level 1
Asset included in:
Financial Assets	3,437,041	7,743,765
Level 1 | Cash and Cash Equivalents | Money Market Securities
Asset included in:
Financial Assets	2,134,721	6,443,102
Level 1 | Investments Available-for-sale at Fair Value | U.S. Government Obligations
Asset included in:
Financial Assets	1,302,320	1,300,663
Level 2
Asset included in:
Financial Assets	1,308,508	3,004,238
Level 2 | Investments Available-for-sale at Fair Value | Corporate Debt Securities
Asset included in:
Financial Assets	$ 1,308,508	$ 3,004,238

Fair Value Instruments - Additi

Fair Value Instruments - Additional Information (Details)	3 Months Ended
	Mar. 31, 2017USD ($)
Fair Value Disclosures [Abstract]
Fair value assets, Level 1 to Level 2 transfers, Amount	$ 0
Fair value, assets, Level 2 to Level 1 transfers, Amount	0
Fair value, liabilities, Level 1 to Level 2 transfers, Amount	0
Fair value, liabilities, Level 2 to Level 1 transfers, Amount	0
Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into Level 3	0
Fair value, measurement with unobservable inputs reconciliation, recurring Basis, asset, transfers out of Level 3	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers into Level 3	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers out of Level 3	$ 0

Available for Sale Securities -

Available for Sale Securities - Summary of Available-for-sale Securities (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 2,611,564	$ 4,305,991
Gross Unrealized Gains		512
Gross Unrealized Losses	(736)	(1,602)
Fair Value (Net Carrying Amount)	2,610,828	4,304,901
U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	1,302,498	1,300,151
Gross Unrealized Gains		512
Gross Unrealized Losses	(178)
Fair Value (Net Carrying Amount)	1,302,320	1,300,663
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	1,309,066	3,005,840
Gross Unrealized Losses	(558)	(1,602)
Fair Value (Net Carrying Amount)	$ 1,308,508	$ 3,004,238

Available for Sale Securities44

Available for Sale Securities - Additional Information (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Schedule Of Available For Sale Securities [Line Items]
Net unrealized holding gains	$ 354	$ 39,351
Available-For-Sale Securities
Schedule Of Available For Sale Securities [Line Items]
Other-than-temporary impairment	$ 0		$ 0

Available for Sale Securities45

Available for Sale Securities - Summary of Contractual Maturities of Debt Investment Securities (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	$ 2,610,828
Fair Value (Net Carrying Amount)	2,610,828	$ 4,304,901
U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	1,302,320
Fair Value (Net Carrying Amount)	1,302,320	1,300,663
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	1,308,508
Fair Value (Net Carrying Amount)	$ 1,308,508	$ 3,004,238

Available for Sale Securities46

Available for Sale Securities - Summary of Debt Securities with Unrealized Losses (Details)	Mar. 31, 2017USD ($)
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year, Fair Value	$ 1,302,320
Under 1 Year, Gross Unrealized Losses	(178)
1 to 2 Years, Fair Value	1,308,508
1 to 2 Years, Gross Unrealized Losses	(558)
Total, Fair Value	2,610,828
Total, Gross Unrealized Losses	(736)
U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year, Fair Value	1,302,320
Under 1 Year, Gross Unrealized Losses	(178)
Total, Fair Value	1,302,320
Total, Gross Unrealized Losses	(178)
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
1 to 2 Years, Fair Value	1,308,508
1 to 2 Years, Gross Unrealized Losses	(558)
Total, Fair Value	1,308,508
Total, Gross Unrealized Losses	$ (558)

Summary Of Property and Equipme

Summary Of Property and Equipment (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Property Plant And Equipment [Abstract]
Office equipment	$ 461,690	$ 447,580
Leasehold improvements	1,847,378	1,847,378
Laboratory and manufacturing equipment	2,732,841	2,659,621
Field equipment	131,096	131,096
Software	150,452	150,451
Construction in progress	199,273	176,963
Total property and equipment, gross	5,522,730	5,413,089
Less: accumulated depreciation and amortization	(2,438,937)	(2,142,892)
Property and equipment, net	$ 3,083,793	$ 3,270,197

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Property Plant And Equipment [Abstract]
Depreciation and leasehold improvement amortization expense	$ 296,045	$ 357,023

Summary of Accrued Liabilities

Summary of Accrued Liabilities (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Employee compensation and benefits	$ 750,760	$ 1,088,773
Employee compensation for future absences	201,381	173,533
Interest	71,535	82,591
Professional fees	39,145	79,029
Other	219,126	246,360
Total accrued liabilities	$ 1,281,947	$ 1,670,286

Debt Obligations - Principal Re

Debt Obligations - Principal Repayments Due Under Term Loan (Details) - Term Loan	Mar. 31, 2017USD ($)
Debt Instrument [Line Items]
2,017	$ 4,843,170
2,018	5,163,821
Total Growth Term Loan payments	10,006,991
Less discount and deferred financing costs	(203,380)
Plus final fee premium	551,279
Total Growth Term Loan, net	$ 10,354,890

Other Agreements - Additional I

Other Agreements - Additional Information (Details)	3 Months Ended
	Mar. 31, 2017USD ($)
Other Agreements [Line Items]
Percentage on annual revenues for cash consideration to be paid	6.00%
Minimum | NuvoGen Asset Purchase Agreement
Other Agreements [Line Items]
Asset purchase agreement quarterly installments due from beginning 2018	$ 400,000

Other Agreements - Schedule of

Other Agreements - Schedule of Minimum Remaining Payments Due (Details) - NuvoGen Asset Purchase Agreement	Mar. 31, 2017USD ($)
Purchase Obligation Fiscal Year Maturity [Line Items]
2,017	$ 600,000
2,018	400,000
2,019	400,000
2,020	400,000
2,021	400,000
2022 and beyond	6,298,743
Total NuvoGen obligation payments	8,498,743
Less discount	(26,512)
Total NuvoGen obligation, net	$ 8,472,231

Net Loss per Share - Reconcilia

Net Loss per Share - Reconciliation of Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Share (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Numerator:
Net loss	$ (5,816,274)	$ (7,026,424)
Denominator:
Weighted-average shares outstanding-basic and diluted	7,971,097	6,885,522
Net loss per share, basic and diluted	$ (0.73)	$ (1.02)

Net Loss per Share - Outstandin

Net Loss per Share - Outstanding Options, Warrants and Restricted Stock Units Excluded from Computation of Diluted Net Loss per Share (Detail) - shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Options to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	1,441,924	1,045,060
Restricted Stock Units R S U
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	256,499	27,500
Warrant | Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	219,723	219,723

Stockholders Deficit - Addition

Stockholders Deficit - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended
	Jan. 31, 2017	Mar. 31, 2017	Dec. 31, 2016
Employee Stock Option
Class Of Stock [Line Items]
Number of additional shares authorized	211,500
Restricted Stock Units R S U
Class Of Stock [Line Items]
Unrecognized compensation expense		$ 384,164
Compensation expense period expected to be recognized		7 months 6 days
Number of shares unvested and outstanding		256,499	355,499
Number of shares vested and unissued		55,000
Number of shares unvested		201,499
Two Thousand Fourteen Equity Incentive Plan
Class Of Stock [Line Items]
Number of shares available for issuance		110,215
Options to purchase common stock outstanding		1,441,924
Options fully vested		674,270
Two Thousand Fourteen Equity Incentive Plan | Employee Stock Option
Class Of Stock [Line Items]
Options to purchase common stock outstanding		1,441,924	1,161,705
Unrecognized compensation expense		$ 1,181,357
Compensation expense period expected to be recognized		1 year 10 months 2 days
Board Of Directors
Class Of Stock [Line Items]
Retirement of treasury stock, shares	1,396

Stockholders Deficit - Summary

Stockholders Deficit - Summary of Stock Option Plans Activity (Details) - Two Thousand Fourteen Equity Incentive Plan - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Ending Balance	1,441,924
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Beginning Balance	1,161,705
Number of Shares, Granted	300,500
Number of Shares, Exercised	(13,116)
Number of Shares, Forfeited	(5,566)
Number of Shares, Expired/Cancelled	(1,599)
Number of Shares, Ending Balance	1,441,924	1,161,705
Number of Shares, Exercisable	674,270
Weighted-Average Exercise Price Per Share, Beginning Balance	$ 3.35
Weighted-Average Exercise Price Per Share, Granted	1.81
Weighted-Average Exercise Price Per Share, Exercised	2.67
Weighted-Average Exercise Price Per Share, Forfeited	3.49
Weighted-Average Exercise Price Per Share, Expired/Cancelled	6.79
Weighted-Average Exercise Price Per Share, Ending Balance	3.03	$ 3.35
Weighted-Average Exercise Price Per Share, Exercisable	$ 3.40
Weighted-Average Remaining Contractual Life, Outstanding	7 years 10 months 24 days	7 years 8 months 12 days
Weighted-Average Remaining Contractual Life, Exercisable	6 years 6 months
Aggregate Intrinsic Value, Balance	$ 5,934,530	$ 36,887
Aggregate Intrinsic Value, Exercised	47,025
Aggregate Intrinsic Value, Exercisable	$ 2,577,267

Stockholders Deficit - Summar57

Stockholders Deficit - Summary of Material Factors Incorporated in Black-Scholes Model in Estimating Fair Value of Options Granted (Details)	1 Months Ended
	Jan. 31, 2017$ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	1.92%
Expected volatility	61.64%
Expected term	5 years 2 months 5 days
Expected dividend yield	0.00%
Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock	$ 1.75

Stockholders Deficit - Summar58

Stockholders Deficit - Summary of RSU Plans Activity (Details) - Restricted Stock Units R S U	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Restricted Stock Units (RSU)
Balance at December 31, 2016 | shares	355,499
Granted | shares	10,000
Exercised | shares	(109,000)
Balance at March 31, 2017 | shares	256,499
Weighted Average Grant Date Fair Value Per Share
Balance at December 31, 2016 | $ / shares	$ 2.41
Granted | $ / shares	1.75
Exercised | $ / shares	2.44
Balance at March 31, 2017 | $ / shares	$ 2.38

Stockholders Deficit - Summar59

Stockholders Deficit - Summary of Stock-Based Compensation (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	$ 396,646	$ 170,048
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	279,583	121,550
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	88,361	37,734
Cost of Revenue
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	$ 28,702	$ 10,764

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	3 Months Ended
	Mar. 31, 2017USD ($)
Commitments And Contingencies [Line Items]
Lease expiration term	The Company leases office and laboratory space in Tucson, Arizona under two non-cancelable operating leases.
Lease equipment financing arrangement	$ 21,000
Lease expiration date of lease payments not in schedule	2017-12
Computer Equipment
Commitments And Contingencies [Line Items]
Capital lease commitments	$ 104,000
Computer Equipment | Minimum
Commitments And Contingencies [Line Items]
Capital lease commitment period	36 months
Computer Equipment | Maximum
Commitments And Contingencies [Line Items]
Capital lease commitment period	48 months

Commitments and Contingencies61

Commitments and Contingencies - Minimum Real Estate Lease Payments Before Common Area Maintenance Charges (Details)	Mar. 31, 2017USD ($)
Commitments And Contingencies Disclosure [Abstract]
2,017	$ 382,544
2,018	512,533
2,019	514,977
2,020	517,457
2,021	43,139
Total minimum lease payments	$ 1,970,650

Commitments and Contingencies62

Commitments and Contingencies - Schedule Of Product Warranty Liability (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Beginning balance	$ 50,426	$ 20,213
Cost of warranty claims	(173)	(2,898)
Warranty accrual	(12,561)	29,892
Ending balance	$ 37,692	$ 47,207

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income tax examination, likelihood of unfavorable settlement	greater than 50 percent
Uncertain tax positions	$ 0		$ 0
Accrued interest or penalties	0		$ 0
Recognized interest or penalties	$ 0	$ 0

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Related Party Transaction [Line Items]
Common stock value	$ 8,059	$ 7,938
QIAGEN North American Holdings Incorporation
Related Party Transaction [Line Items]
Common stock value	2,000,000
Minimum | QIAGEN North American Holdings Incorporation
Related Party Transaction [Line Items]
Sale of stock in a financing transaction	$ 12,000,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($)	May 12, 2017	Apr. 13, 2017	Mar. 31, 2017	Dec. 31, 2016
Subsequent Event [Line Items]
Common stock, par value			$ 0.001	$ 0.001
Legal fees capitalized as deferred offering costs			$ 77,700
Subsequent Event | Bonus Award | Named Executive Officer
Subsequent Event [Line Items]
Performance based retention and incentive bonus award		$ 302,000
Aggregate gross proceeds to provide bonus award		$ 12,000,000
Bonus award, description		No Bonus Awards will be earned or paid if the Financing Goal does not occur.
Aggregate percentage of corporate goal achieved		47.50%
Subsequent Event | Sales Agreement
Subsequent Event [Line Items]
Common stock, par value		$ 0.001
Shares of common stock sold	1,775,367
Gross proceeds from issuance of common stock	$ 10,000,000
Net proceeds from issuance of common stock	$ 9,600,000
Subsequent Event | Maximum | Sales Agreement
Subsequent Event [Line Items]
Common stock aggregate offering price		$ 20,000,000